New and very expensive forms of radiotherapy, such as intensity-modulated radiation therapy and proton therapy, have taken over the localized prostate cancer market. But is there enough evidence to justify their increased utilization and if so, how can we possibly afford them?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sox, H. & Greenfield, S. Initial National Priorities for Comparative Effectiveness Research. Institute of Medicine of the National Academies [online], (2009).
Sheets, N. C. et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA 307, 1611–1620 (2012).
Pollack, A. et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 53, 1097–1105 (2002).
Dearnaley, D. P. et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 8, 475–487 (2007).
Zietman, A. L. et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95–09. J. Clin. Oncol. 28, 1106–1111 (2010).
Trinh, Q. D. et al. Perioperative outcomes of robot-assisted radical prostatectomy compared with open radical prostatectomy: results from the nationwide inpatient sample. Eur. Urol. 61, 679–685 (2012).
Nguyen, P. L. et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J. Clin. Oncol. 29, 1517–1524 (2011).
Zietman, A. L. The Titanic and the Iceberg: prostate proton therapy and health care economics. J. Clin. Oncol. 25, 3565–3566 (2007).
Goitein, M. & Cox, J. D. Should randomized clinical trials be required for proton radiotherapy? J. Clin. Oncol. 26, 175–176 (2008).
Carreyrou, J. & Tamman, M. A device to kill cancer, lift revenue. Wall Street Journal [online], (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Murphy, D., Williams, S. & Cooperberg, M. New types of radiotherapy improve cancer outcome but at what cost?. Nat Rev Urol 9, 415–417 (2012). https://doi.org/10.1038/nrurol.2012.137
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2012.137
